ARNA - Arena Pharmaceuticals, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Arena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31
• All eyes on Pfizer Q4 earnings amid bolstered COVID-19 vaccine forecast
• Will the poor performance of biotechs in January be a barometer for 2022? Look to 2016
• One of the largest biotech ETFs has the second highest short interest float of U.S. ETFs
• Bill Gross questions low interest rates to near 40-year high inflation dynamic
• Arena Pharmaceuticals reports grants to its 16 new employees
• Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022
• Why does Pfizer's $6.7B acquisition of Arena Pharmaceuticals make sense? Etrasimod
• Arena Pharmaceuticals, BELLUS Health leads healthcare gainers; IGM Biosciences (IGMS) -41%, X4 Pharmaceuticals XFOR -32%
• Arena Pharma rockets 95% on acquisition by Pfizer
• Arena Pharma achieves target enrollment for etrasimod Cultivate Study A
• Top-line data for late-stage Arena ulcerative colitis candidate expected in Q1 2022
• Arena Pharmaceuticals EPS misses by $0.74
• Arena Pharmaceuticals Q3 2021 Earnings Preview
• Small biotechs warn Biden, lawmakers on drug price bill impact on R&D
• Arena Pharmaceuticals EPS misses by $0.22
• Arena Pharmaceuticals Q2 2021 Earnings Preview
• Arena Pharmaceuticals rebounds as Cantor highlights value of deal with Aristea
• Arena Pharmaceuticals and Aristea ink RIST4721 collaboration agreement
• Arena Pharmaceuticals names Doug Manion as executive vice president of research & development